In a 52 week trial of adult insulin experienced type 1 diabetes patients, 68.9% of patients who received TRESIBA were positive at baseline for anti insulin degludec antibodies and 12.3% of the patients developed anti insulin degludec antibodies at least once during the trial
This medication works by activating GLP-1 receptors in the body, which play a vital role in regulating appetite and glucose metabolism
At Polar Bear Meds, we believe access to life-saving medication shouldnt come with hoops or false promises
doi: 10.3389/fvets.2023.1220213 Received 15 May 2023 Accepted 17 July 2023 Published 10 August 2023 Volume 10 - 2023 Edited by Huansheng Yang, Hunan Normal University, China Reviewed by Dan Yi, Wuhan Polytechnic University, China
Oral conditions with increased melanin pigmentation are common
Yet only 43% of GLP-1 users even reach the minimum 1.2 gram target, and a mere 5% hit the optimal 2.0 gram goal